- Drug policies should be developed through a structured and objective assessment of priorities and evidence.
- All activities should be undertaken in full compliance with international human rights law.
- Drug policies should focus on reducing the harmful consequences rather than the scale of drug use and markets.
- Policy and activities should seek to promote the social inclusion of marginalised groups, and not focus on punitive measures towards them.
- Governments should build open and constructive relationships with civil society in the discussion and delivery of their strategies.
The applicant must normally be a legally constituted and not-for-profit non-governmental organisation and/or network. IDPC will consider applications from non-legally constituted networks on a case-by-case basis.
Applications from organisations that represent – or receive the majority of their funding from – industries for alcohol, tobacco, pharmaceuticals, or other drugs will be reviewed in detail by the Membership Review Committee of the IDPC Board. If there is potential for the organisation’s views and actions to be adversely impacted by vested interests, and that this might undermine the work of IDPC, then the application will be rejected.
The applicant must have a demonstrable track record in a policy field relevant to national, regional and international drug policy, and demonstrate the ability for credible and constructive engagement with policy makers.
The applicant’s work must have national, regional and/or international geographical coverage.
The applicant must add to the geographic and/or thematic coverage of IDPC.
Applications from organisations from countries or specific fields of interest that are already well represented in the IDPC Network will be reviewed in detail by the Membership Review Committee of the IDPC Board, to ensure that IDPC membership remains balanced across regions and thematic areas. In this regard, if the applicant is a member of a national umbrella organisation or network which is already an IDPC member, then their application will likely be rejected.
Applicants whose work and mission focuses on a single substance or issue within the drug policy reform agenda must demonstrate their commitment to broader drug policy reform